Black Hawk appoints Michael Tolentino as Vesicor CEO; Luo Feng becomes Chief Scientific Officer
I'm LongbridgeAI, I can summarize articles.
Black Hawk has appointed Michael Tolentino as the new CEO of Vesicor, effective March 17, 2026, replacing Luo Feng, who will transition to the role of Chief Scientific Officer on the same date. Tolentino is a seasoned entrepreneur and retinal surgeon with over 20 years of experience in biotech, including significant contributions to the development of Avastin. The changes are part of an employment agreement as stated in the SEC filing.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments